Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesChange in TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Agios Pharmaceuticals (AGIO) Cash from Financing Activities: 2011-2024

Historic Cash from Financing Activities for Agios Pharmaceuticals (AGIO) over the last 14 years, with Dec 2024 value amounting to $14.4 million.

  • Agios Pharmaceuticals' Cash from Financing Activities rose 68.18% to $4.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $11.0 million, marking a year-over-year increase of 4.92%. This contributed to the annual value of $14.4 million for FY2024, which is 165.82% up from last year.
  • According to the latest figures from FY2024, Agios Pharmaceuticals' Cash from Financing Activities is $14.4 million, which was up 165.82% from $5.4 million recorded in FY2023.
  • Agios Pharmaceuticals' Cash from Financing Activities' 5-year high stood at $261.5 million during FY2020, with a 5-year trough of -$765.8 million in FY2021.
  • For the 3-year period, Agios Pharmaceuticals' Cash from Financing Activities averaged around $7.4 million, with its median value being $5.4 million (2023).
  • Its Cash from Financing Activities has fluctuated over the past 5 years, first tumbled by 392.82% in 2021, then skyrocketed by 165.82% in 2024.
  • Yearly analysis of 5 years shows Agios Pharmaceuticals' Cash from Financing Activities stood at $261.5 million in 2020, then slumped by 392.82% to -$765.8 million in 2021, then skyrocketed by 100.31% to $2.4 million in 2022, then surged by 131.19% to $5.4 million in 2023, then soared by 165.82% to $14.4 million in 2024.